Identification
- Summary
Calcium glubionate is a calcium salt indicated in the treatment of hypocalcemia, hyperkalemia, lead poisoning, and as an adjunct in the treatment of exudative skin conditions.
- Generic Name
- Calcium glubionate anhydrous
Commonly known or available as Calcium glubionate - DrugBank Accession Number
- DB13142
- Background
Calcium glubionate (or glubionate calcium) is a mineral supplement to prevent or treat low blood calcium levels in people who do not get enough calcium from their diets.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Calcium glubionate anhydrous (DB13142)
- Weight
- Average: 592.513
Monoisotopic: 592.1163697 - Chemical Formula
- C18H32CaO19
- Synonyms
- (D-gluconato)(lactobionato)calcium
- Calcium D-gluconate lactobionate
- Calcium glubionate anhydrous
- Glubionate calcium
Pharmacology
- Indication
Calcium glubionate is indicated to treat conditions caused by low calcium levels such as bone loss (osteoporosis), weak bones (osteomalacia/rickets), decreased activity of the parathyroid gland (hypoparathyroidism), and a certain muscle disease (latent tetany). It may also be used in certain patients to make sure they are getting enough calcium (e.g., women who are pregnant, nursing, or postmenopausal, people taking certain medications such as phenytoin, phenobarbital, or prednisone).
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
Essential for nervous, muscular, and skeletal systems. Maintain cell membrane and capillary permeability. Act as an activator in the transmission of nerve impulses and contraction of cardiac, skeletal, and smooth muscle. Essential for bone formation and blood coagulation.
- Absorption
Minimal unless chronic, high doses; absorption predominantly in the duodenum and dependent on calcitriol and vitamin D; mean absorption of calcium intake varies with age (infants 60%, prepubertal children 28%, pubertal children 34%, adults 25%); during pregnancy, calcium absorption doubles; calcium is absorbed in soluble, ionized form; solubility of calcium is increased in an acid environment (IOM 2011); decreased absorption occurs in patients with achlorhydria, renal osteodystrophy, steatorrhea, or uremia
- Volume of distribution
Primarily in bones, teeth
- Protein binding
~40%, primarily to albumin
- Metabolism
- Not Available
- Route of elimination
Primarily feces (75%; as unabsorbed calcium); urine (22%)
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Assess patient for nausea, vomiting, anorexia, thirst, severe constipation, paralytic ileus, and bradycardia
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcebutolol The therapeutic efficacy of Acebutolol can be decreased when used in combination with Calcium glubionate anhydrous. Acetyldigitoxin Calcium glubionate anhydrous may increase the arrhythmogenic and cardiotoxic activities of Acetyldigitoxin. Alendronic acid The serum concentration of Alendronic acid can be decreased when it is combined with Calcium glubionate anhydrous. Alfacalcidol The risk or severity of adverse effects can be increased when Alfacalcidol is combined with Calcium glubionate anhydrous. Amiodarone The therapeutic efficacy of Amiodarone can be decreased when used in combination with Calcium glubionate anhydrous. Amlodipine The therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium glubionate anhydrous. Atenolol The therapeutic efficacy of Atenolol can be decreased when used in combination with Calcium glubionate anhydrous. Bendroflumethiazide Bendroflumethiazide may decrease the excretion rate of Calcium glubionate anhydrous which could result in a higher serum level. Benzthiazide Benzthiazide may decrease the excretion rate of Calcium glubionate anhydrous which could result in a higher serum level. Bepridil The therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium glubionate anhydrous. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Calcium glubionate 3CF7K0SD0Q 12569-38-9 OKRXSXDSNLJCRS-NLOQLBMISA-L - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image CALCIUM SANDOZ 10 ML 1,375 GR AMPUL, 5 ADET Calcium glubionate (1375 mg/10ml) Injection Intramuscular; Intravenous NOVARTİS SAĞLIK GIDA VE TARIM ÜRÜNLERİ SAN. VE TİC. A.Ş. 2020-08-14 Not applicable Turkey 
Categories
- ATC Codes
- A12AA02 — Calcium glubionate
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 93H20IU3DN
- CAS number
- 97635-31-9
- InChI Key
- YPCRNBPOUVJVMU-LCGAVOCYSA-L
- InChI
- InChI=1S/C12H22O12.C6H12O7.Ca/c13-1-3(15)10(7(18)8(19)11(21)22)24-12-9(20)6(17)5(16)4(2-14)23-12;7-1-2(8)3(9)4(10)5(11)6(12)13;/h3-10,12-20H,1-2H2,(H,21,22);2-5,7-11H,1H2,(H,12,13);/q;;+2/p-2/t3-,4-,5+,6+,7-,8-,9-,10-,12+;2-,3-,4+,5-;/m11./s1
- IUPAC Name
- {[(2R,3R,4R,5R)-2,3,5,6-tetrahydroxy-4-{[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}hexanoyl]oxy}calcio (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate
- SMILES
- OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(=O)O[Ca]OC(=O)[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO
References
- General References
- External Links
- PubChem Compound
- 131704325
- PubChem Substance
- 347829259
- ChemSpider
- 58310
- ChEMBL
- CHEMBL2219740
- Wikipedia
- Calcium_glubionate
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection Intramuscular; Intravenous Injection Intramuscular; Intravenous 1375 mg/10ml - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 47.2 mg/mL ALOGPS logP -2.5 ALOGPS logP -9.6 Chemaxon logS -1.1 ALOGPS pKa (Strongest Acidic) 11.32 Chemaxon pKa (Strongest Basic) -3.6 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 17 Chemaxon Hydrogen Donor Count 13 Chemaxon Polar Surface Area 334.05 Å2 Chemaxon Rotatable Bond Count 17 Chemaxon Refractivity 107.1 m3·mol-1 Chemaxon Polarizability 50.17 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at November 04, 2016 20:50 / Updated at June 12, 2021 10:55